Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
ROHI, just one MM left at .65, then off to .70s !!!!!
BJCT, one nasty azzed spread
AXMP bid UT, ready to fly here
ROHI 25k just went through at ask, ready to run over $1 soon
only if it's in one of their electric cars
hold up, you might get it at .03 in a few minutes
MVIS 200 day MA broken on news pre-market this morning, looking for $4+ today
MVIS nice PM
MVIS on watch, nice news this morning on 8.5 million dollar order
CDCS news PM
CDC Software’s Cloud-Based On-Demand eCommerce Platform to Integrate with Bidz.com’s Premier Auction Marketplace
Integration Part of Strategic Partnership with One of North America’s Leading Jewelry Auctioneers
ATLANTA & SHANGHAI--(BUSINESS WIRE)--CDC Software (NASDAQ: CDCS), a global provider of enterprise software applications and services, today announced it plans to integrate its cloud-based on-demand eCommerce platform with one of North America’s premier auction marketplaces as part of a strategic partnership with Bidz.com (NASDAQ: BIDZ), a leading online jewelry auctioneer in North America.
“Customers can utilize this new channel to help increase their sales and ultimately grow their bottom line.”
This partnership is expected to help CDC eCommerce customers, that include some of the world’s leading brand manufacturers and retailers, increase sales volume, as well as leverage an alternate channel of distribution for their products. As part of this partnership, customers can list items, like consumer electronics, computers and sports related products, which are not specialities of this jewelry auctioneer, exclusively into Bidz.com through its CDC cloud-based eCommerce system. This will help CDC eCommerce customers’ help increase online sales though auctioning off excess inventory into a highly visible distribution channel. In turn, CDC eCommerce customers also will provide Bidz.com with access to products beyond jewelry which helps them expand in the growing online auction marketplace.
CDC eCommerce is a cloud-based on-demand eCommerce platform based on a 100 percent multi-tenant architecture that helps retailers and manufacturers effectively sell products through multiple online sales channels and across international boundaries. CDC eCommerce powers more than 150 ecommerce sites in 10 countries that include some of the world’s leading brands such as Sirius XM Satellite Radio, Dell Financial Services, Philips, Major League Baseball, Wolford, Genco, American Airlines, National Football League (NFL), Sears, Starwood, United Airlines and National Hockey League (NHL).
Bidz.com offers live auctions on its website 24 hours a day, seven days a week. Bidz.com also features a unique live auction process where bidding ends at a preset deadline, unlike other sites where auctions can last for days. Bidz.com auctions are fast-paced with auctions that last as long as there are bidding, and close if there has not been a bid in 15 seconds.
“This partnership provides CDC Software with a new exclusive distribution channel for customers while adding additional opportunities for transactional revenue,” said Gary Black, general manager of CDC eCommerce product line of CDC Software. “Customers can utilize this new channel to help increase their sales and ultimately grow their bottom line.”
“We are delighted to partner with CDC Software and provide their world class customers exclusive access to our unique auction marketplace,” said Leon Kuperman, president of Bidz.com. “We believe that Bidz.com can help bring these customers’ excess inventory into a highly visible distribution channel that has bidders from as many as 130 countries. CDC eCommerce customers also will provide us with access to products beyond jewelry that will help us expand even further in the growing online auction marketplace.”
About Bidz.com
Bidz.com, founded in 1998, is a leading online retailer of jewelry. Bidz offers its products through a live auction format as well as a fixed price online retail store, Buyz.com. Bidz.com's auctions are also available in Arabic, German and Spanish. To learn more about Bidz.com visit its website at www.bidz.com, which is not part of this press release. Bidz also operates Modnique, a division of Bidz.com, an exclusive private sale shopping site for members-only, offering authentic premium brand name merchandise. Modnique offers its members exclusive access to 24-72 hour sales events on designer apparel, accessories, shoes, and houseware and much more at price points up to 85 percent below traditional retail prices. To learn more about Modnique visit its website at www.modnique.com, which is not part of this press release.
About CDC eCommerce
CDC eCommerce (www.cdcecommerce.com) is a leading cloud-based on-demand eCommerce platform for retailers and manufacturers that helps them effectively sell products through multiple online sales channels and across international boundaries. Powering more than 150 ecommerce sites in 10 countries, CDC eCommerce provides its client base with a unique combination of technology and professional services, allowing these organizations to effectively outsource core elements of their eCommerce operations. Many of the most well respected brands in the world, such as Sirius Satellite Radio, Major League Baseball, and Dell Financial Services, use CDC eCommerce.
About CDC Software
CDC Software (NASDAQ: CDCS), The Customer-Driven Company™, is a provider of enterprise software applications and a full range of services designed to help organizations deliver a superior customer experience, while increasing efficiencies and profitability. Leveraging a service-oriented architecture (SOA), CDC Software offers multiple delivery options for their solutions including on-premise, hosted, cloud-based Software as a Service (SaaS) or blended-hybrid deployment offerings. CDC Software’s solutions include enterprise requirements planning (ERP), manufacturing operations management, enterprise manufacturing intelligence, supply chain management (demand management, order management and warehouse and transportation management), e-Commerce, human capital management, customer relationship management (CRM), complaint management and aged care solutions.
CDC Software’s recent acquisitions are part of its “acquire, integrate, innovate and grow” strategy. Fueling the success of this strategy is the company’s global scalable business and technology infrastructure featuring multiple complementary applications and services, domain expertise in vertical markets, cost effective product engineering centers in India and China, a highly collaborative and fast product development process utilizing Agile methodologies, and a worldwide network of direct sales and channel operations. This strategy has helped CDC Software deliver innovative and industry-specific solutions to more than 6,000 customers worldwide within the manufacturing, distribution, transportation, retail, government, real estate, financial services, health care, and not-for-profit industries. For more information, please visit www.cdcsoftware.com.
Cautionary Note Regarding Forward-Looking Statements
This press release includes "forward-looking statements" within the meaning of the United States Private Securities Litigation Reform Act of 1995. These forward-looking statements include statements regarding our and bidz.com expectations regarding this strategic partnership and relationship and the potential benefits of this relationship to each party and their respective customers including potential increases in sales volumes, our beliefs and expectations regarding this partnership to target markets, our beliefs regarding the intentions and beliefs of both parties relating to market expansion and penetration and performance under this strategic partnership, our beliefs relating to the leveraging of the Bidz.com auction marketplace by CDC eCommerce customers, our expectations and those of bidz.com with respect to market and customer needs, demands and preferences, and other statements that are not historical fact, the achievement of which involve risks, uncertainties and assumptions. If any such risks or uncertainties materialize or if any of the assumptions proves incorrect, our results could differ materially from the results expressed or implied by the forward-looking statements we make. These statements are based on management's current expectations and are subject to risks and uncertainties and changes in circumstances. There are important factors that could cause actual results to differ materially from those anticipated in the forward looking statements, including the following: (a) the ability to realize strategic objectives by taking advantage of market opportunities; (b) the ability to make changes in business strategy, development plans and product offerings to respond to the needs of current, new and potential customers, in the process manufacturing industries; (c) the ability to address technological changes and developments including the development and enhancement of products; (d) the fulfillment of contractual obligations by our partners. Further information on risks or other factors that could cause results to differ is detailed in our filings or submissions with the United States Securities and Exchange Commission, and those of our ultimate parent company, CDC Corporation, located at www.sec.gov. All forward-looking statements included in this press release are based upon information available to management as of the date of the press release, and you are cautioned not to place undue reliance on any forward looking statements which speak only as of the date of this press release. The company assumes no obligation to update or alter the forward looking statements whether as a result of new information, future events or otherwise. Historical results are not indicative of future performance.
Contacts
CDC Corporation
Investor Relations:
Monish Bahl, 678-259-8510
mbahl@cdcsoftware.com
or
Media Relations:
CDC Software
Lorretta Gasper, 678-259-8631
lgasper@cdcsoftware.com
or
Bidz Investor Relations:
Addo Communications, Inc.
Andrew Greenebaum, 310-829-5400
andrewg@addocommunications.com
Permalink: http://www.businesswire.com/news/home/20100405005519/en/CDC-Software%E2%80%99s-Cloud-Based-On-Demand-eCommerce-Platform-Integrate
DYAX news PM
First-Ever Published Study Underscores Significant Economic Burden of Hereditary Angioedema on Patients, Families and the Healthcare System
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Dyax Corp. (NASDAQ: DYAX) announced the publication of a first-ever comprehensive examination of the economic burden associated with the treatment of acute attacks and chronic management of hereditary angioedema (HAE). The results, published today in the Annals of Allergy, Asthma, and Immunology, bring to light the substantial direct and indirect medical costs of the disease on patients, payers and society. The economic study is one component of a larger survey-based Burden of Illness (BOI) study which assessed both the economic and humanistic burden of HAE. The BOI study was conducted by Dyax in conjunction with the United States Hereditary Angioedema Association (HAEA) and United Biosource Corporation (UBC).
“I have made several sacrifices in my career and personal life because of HAE. The unpredictability and frequency of my laryngeal attacks have made it impossible for me to continue working as a computer operator and, as a result, I’ve been out of work for twelve years”
Monetizable and non-monetizable costs were captured in the study and highlighted HAE’s costly and detrimental impact for patients, payers and society. Monetizable costs averaged $42,000 annually per HAE patient. Costs included direct costs associated with emergency care, physician visits, hospital stays, tests and procedures, and medications, as well as indirect costs such as missed work days and reduced productivity. Costs increased with disease severity. Patients who reported their most recent attack as severe amassed an estimated $96,000 in annual per patient costs. The largest cost component, accounting for approximately 48% of total costs for the average HAE patient, is emergency room visits and hospital stays for managing acute attacks.
Additional non-monetizable costs were reflected in the study yet were not part of the quantifiable analysis. These costs, which further exacerbate the economic burden on patients, payers and society, included the burden of increased depression, reduced income potential and missed opportunities. These non-monetizable costs consist of the cost of managing depression (42.5% percent of patients showed signs of at least mild depression and 19.5% reported that they were taking psychotropic or antidepressant medication), and the financial consequence of common activities being impacted such as driving, exercising and studying. Other costs that were not part of the analyses include the expense of improper procedures and medications as well as indirect costs related to non-paid caregivers. As such, these compounding costs underestimate the total costs associated with HAE.
“I have made several sacrifices in my career and personal life because of HAE. The unpredictability and frequency of my laryngeal attacks have made it impossible for me to continue working as a computer operator and, as a result, I’ve been out of work for twelve years,” said Joan Angert, who was not officially diagnosed with HAE until nine years ago, though she suffered from its symptoms for 30 years.
HAE is a rare genetic disease characterized by unpredictable acute episodes of severe, often painful swelling affecting the extremities, abdomen and the larynx. On average, participants experienced 26.9 acute attacks per year. HAE is estimated to affect 1:10,000 to 1:50,000 individuals. More than half (56.5%) of the respondents from the study reported that they experienced painful abdominal symptoms for their most recent attacks while 24.5% reported laryngeal symptoms. Laryngeal attacks pose the greatest risk with the potential for asphyxiation.
“Our study provides a comprehensive survey of the burden patients with HAE live with,” explained lead author David Wilson, MA, Assistant Professor, MGH Institute of Health Professions. “The breadth of the economic consequences highlighted in this study hopefully will raise people’s understanding of the disease and inform them of the value of having new therapies available for the people with HAE.”
Study Methodology
The Burden of Illness study, developed in consultation with expert health economists, HAE experts, and HAE patients, was conducted from November 2007 to January 2008. Study participants were recruited using the HAEA database of HAE patients. The study collected responses from 457 HAE patients via an Institutional Review Board-approved, web-based survey that solicited information on attack characterization, acute attack treatment, chronic disease management, impact on work and patient costs. A standardized instrument, the Work Productivity and Activity Impairment (WPAI) tool, was included to assess impact on work and productivity. Standard medical costs and U.S. average wage costs were assigned to survey items to assess direct medical and indirect costs, respectively.
About HAE
Hereditary angioedema (HAE) is a rare acute inflammatory condition characterized by episodes of severe, often painful swelling affecting the extremities, the gastrointestinal tract, the genitalia, and in the larynx. HAE is caused by low or dysfunctional levels of C1 esterase inhibitor (C1-INH), a naturally occurring molecule that inhibits plasma kallikrein, a key mediator of inflammation, and other serine proteases in the blood. HAE is estimated to affect 1:10,000 to 1:50,000 individuals. Learn more at www.HAEHope.com.
About Dyax
Dyax is a fully integrated biopharmaceutical company focused on discovering, developing and commercializing novel biotherapeutics for unmet medical needs, with an emphasis on inflammatory and oncology indications. The Company utilizes its proprietary drug discovery technology, phage display, to identify antibody, small protein and peptide compounds for clinical development. Dyax also leverages this technology broadly with over 70 revenue generating licenses and collaborations for therapeutic discovery, as well as in non-core areas such as affinity separations, diagnostic imaging, and research reagents. Dyax is headquartered in Cambridge, Massachusetts. For online information about Dyax Corp., please visit www.dyax.com.
Contacts
Dyax Corp.
Ivana Magovcevic-Liebisch, 617-250-5759
Executive Vice President Corporate Development and General Counsel
imagovcevic@dyax.com
or
Nicole Jones, 617-250-5744
Director, Investor Relations and Corporate Communications
njones@dyax.com
Permalink: http://www.businesswire.com/news/home/20100405005194/en/First-Ever-Published-Study-Underscores-Significant-Economic-Burden
HDNG news, PM
Hardinge’s Board of Directors Unanimously Recommends Rejection of Romi’s Tender Offer
Reiterates That Romi’s Unsolicited Bid is Grossly Inadequate and Opportunistic Files 14D-9 with SEC Detailing Reasons for Board’s Recommendation
ELMIRA, N.Y.--(BUSINESS WIRE)--Hardinge Inc. (NASDAQ: HDNG) (“Hardinge”) today announced that its Board of Directors voted unanimously to recommend that Hardinge shareholders reject Indústrias Romi S.A.’s (Bovespa: ROMI3) (“Romi”) $8.00 per common share cash tender offer (the “Offer”) as grossly inadequate, opportunistic, and not in the best interests of Hardinge and its shareholders.
“or any other merger or other similar business combination with the Company”
The Board noted that it unanimously rejected a proposal from Romi at the same price on February 18, 2010. The Company has filed a Schedule 14D-9 with the Securities and Exchange Commission (“SEC”) detailing the reasons for its rejection of Romi’s offer. The full text of the filing will be available in the Investor Relations section of Hardinge’s website at http://www.hardinge.com and on the SEC website at http://www.sec.gov/.
Kyle H. Seymour, Non-Executive Chairman of the Board of Directors of Hardinge, said, “Our Board’s position remains clear and unanimous – this is an opportunistic attempt by Romi to acquire Hardinge at a grossly inadequate price that fails to reflect the value of our significant industry position, global market presence, and future growth prospects. The Hardinge Board strongly urges shareholders to reject Romi’s offer and not tender their shares.”
Richard L. Simons, President & Chief Executive Officer of Hardinge, added, “Over the past year, we have made substantial progress positioning Hardinge for significantly improved performance, including taking steps that have generated annual fixed cost savings of approximately $30 million. Management and the Board believe that the Company is poised to reap the benefits of its streamlined operating structure and to outperform market improvements as the machine tool industry recovers.”
In making its determination, the Hardinge Board, taking into account advice received from its legal and financial advisors and senior management of the Company, considered numerous factors, including their belief that:
Hardinge is well-positioned to emerge strongly from the current economic downturn and to benefit significantly as the machine tool industry recovers.
* The Board believes that Hardinge and its shareholders are poised to realize significant benefits as the economy emerges from the recession and as industrial production rebounds in Hardinge’s key geographical markets.
* A successful acquisition of Hardinge by Romi at this time would enable Romi, instead of Hardinge shareholders, to capture the benefits of Hardinge’s improved financial performance in such a recovery.
Romi’s Offer is grossly inadequate.
* The Board does not believe that the $8.00 per share price offered by Romi reflects the underlying value of Hardinge’s assets, operations and growth prospects, and the significant additional value that the Board and senior management believe would result from the continued implementation of Hardinge’s strategic plan.
* Various value-creating and cost-saving initiatives have provided additional value to Hardinge and its shareholders that is not reflected in Romi’s Offer. Several initiatives undertaken by Hardinge in 2008 and 2009 have significantly improved the Company’s operating cost structure, working capital levels and business model, generating annual fixed cost savings of approximately $30 million and a significantly reduced breakeven point in U.S. operations.
Romi’s Offer is opportunistic.
* The Board believes that Romi, a fellow industry participant, recognizes the significant medium- and long-term value creation potential of Hardinge’s assets and strategic plan, recent value-creation and cost-saving initiatives and potential returns from the pursuit of new marketplace opportunities, and has opportunistically timed its Offer to acquire Hardinge before the full impact of these factors and the industry’s recovery can be reflected in Hardinge’s results of operations and share price.
* The Board also notes that, even though after Romi first made its $8.00 per share proposal Hardinge announced an approximate $27 million improvement in the funded status of its pension plans, Romi commenced its tender offer at the same $8.00 price previously proposed and rejected without giving any credit for this increased value.
Romi’s Offer values Hardinge at a price significantly below historical valuations.
* Prior to the fourth quarter of 2008, when the economic recession took a significant toll on Hardinge and the machine tool industry as a whole, the market price of Hardinge common stock regularly traded in the double digits, ranging from the mid-teens to significantly higher trading levels in previous periods.
* The Board believes that a return to a double digit stock price for Hardinge’s common shares is realistically attainable in the medium term if management projections are met, with the key variables being how soon the industry will turn upward and the strength of the rebound.
Romi’s Offer is highly conditional.
* The Offer includes over 20 conditions to the obligations of Romi, several of which are vague, have very low thresholds or give Romi broad discretion to determine whether or not they are satisfied, resulting in substantial uncertainty as to whether Romi would be obligated to consummate the Offer.
Romi’s Offer is coercive.
* The Board believes that a tender offer for a small-cap company like Hardinge is structurally coercive. In the Offer, Romi specifically states that shareholders who do not tender their shares may be left holding illiquid securities, because of the small public float and the risk that the issuer is delisted.
* The terms of the Offer further validate this concern and justify the Board’s prior actions. In the Offer, Romi indicates that even if the Offer is consummated, it reserves the right not to propose the second-step merger “or any other merger or other similar business combination with the Company” in the Offer.
Jefferies & Company, Inc. is acting as financial advisor to Hardinge and Wachtell, Lipton, Rosen & Katz is providing legal advice. Questions and requests for assistance regarding the tender offer may be directed to Hardinge’s Information Agent, Okapi Partners LLC, toll-free at (877) 279-2311.
About Hardinge Inc.
Hardinge is a global designer, manufacturer and distributor of machine tools, specializing in SUPER PRECISION™ and precision CNC Lathes, high performance Machining Centers, high-end cylindrical and jig Grinding Machines, and technologically advanced Workholding & Rotary Products. The Company’s products are distributed to most of the industrialized markets around the world with approximately 70% of the 2009 sales outside of North America. Hardinge has a very diverse international customer base and serves a wide variety of end-user markets. This customer base includes metalworking manufacturers which make parts for a variety of industries, as well as a wide range of end users in the aerospace, agricultural, transportation, basic consumer goods, communications and electronics, construction, defense, energy, pharmaceutical and medical equipment, and recreation industries, among others. The Company has manufacturing operations in the United States, Switzerland, Taiwan, and China. Hardinge’s common stock trades on NASDAQ Global Select Market under the symbol, “HDNG.” For more information, please visit http://www.hardinge.com.
This news release contains forward-looking statements (within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended). Such statements are based on management’s current expectations that involve risks and uncertainties. Any statements that are not statements of historical fact or that are about future events may be deemed to be forward-looking statements. For example, words such as "may," "will," "should," "estimates," "predicts," "potential," "continue," "strategy," "believes," "anticipates," "plans," "expects," "intends," and similar expressions are intended to identify forward-looking statements. Hardinge’s actual results or outcomes and the timing of certain events may differ significantly from those discussed in any forward-looking statements due to a variety of factors, including those described in Hardinge’s SEC reports, including its March 15, 2010 Form 10-K. Hardinge undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise. Hardinge notes that forward-looking statements made in connection with a tender offer are not subject to the safe harbors created by the Private Securities Litigation Reform Act of 1995. Hardinge is not waiving any other defenses that may be available under applicable law.
Contacts
Investors:
Hardinge Inc.
Ed Gaio, 607-378-4207
VP & Chief Financial Officer
or
Okapi Partners
Bruce H. Goldfarb / Patrick McHugh
212-297-0720 or 877-279-2311
or
Media:
Sard Verbinnen & Co
Denise DesChenes / Nat Garnick
212-687-8080
Permalink: http://www.businesswire.com/news/home/20100405005555/en/Hardinge%E2%80%99s-Board-Directors-Unanimously-Recommends-Rejection-Romi%E2%80%99s
MVIS news
Microvision Receives $8.5 Million Purchase Order for New PicoP Laser Projection Display Engine
REDMOND, Wash.--(BUSINESS WIRE)--Microvision (NASDAQ:MVIS), a leading developer of ultra-miniature projection display products, announced today that it has received an $8.5 million purchase order for its new ultra-miniature PicoP® laser projection display engine from a consumer electronics customer. The OEM plans to embed the PicoP engine inside a high-end mobile media player for release in late 2010 and plans to announce its launch at that time.
“This embedded application in a high-end mobile media player is part of our strategy to develop multiple premium distribution channels as we continue to advance the PicoP engine design and mature production capacity to meet anticipated demand across a variety of consumer electronic products including handsets.”
Microvision recently announced the completion and shipment of initial samples of its new display engine that incorporates a proprietary ASIC chipset half the original size and weight and that consumes one third less power than its predecessor while delivering uniformly bright, vivid color WVGA (848 X 480) images up to 200 inches. It also provides a 5000:1 contrast ratio – 5 times greater than other pico projector engines in the market today and is always in focus without the need for focusing dials or optics - an especially desirable benefit for mobile consumers.
“We are very pleased to receive the first purchase order for our new display engine,” said Alexander Tokman, President and CEO of Microvision. “This embedded application in a high-end mobile media player is part of our strategy to develop multiple premium distribution channels as we continue to advance the PicoP engine design and mature production capacity to meet anticipated demand across a variety of consumer electronic products including handsets.”
About Microvision (www.microvision.com)
Microvision provides the PicoP display technology platform designed to enable next-generation display and imaging products for pico projectors, vehicles displays, and wearable displays that interface to mobile devices. The company’s projection display engine uses highly efficient laser light sources which can create vivid images with high contrast and brightness. For more information, visit the company’s website (www.microvision.com) and corporate blog (www.microvision.com/displayground).
Forward-Looking Statements Disclaimer
Certain statements contained in this release, including those relating to OEM new product introduction are forward-looking statements that involve a number of risks and uncertainties. Factors that could cause actual results to differ materially from those projected in the Company's forward-looking statements include the following: our ability to raise additional capital when needed; our financial and technical resources relative to those of our competitors; our ability to keep up with rapid technological change; government regulation of our technologies; our ability to enforce our intellectual property rights and protect our proprietary technologies; the ability to obtain additional contract awards; the timing of commercial product launches and delays in product development; the ability to achieve key technical milestones in key products; dependence on third parties to develop, manufacture, sell and market our products; and potential product liability claims and other risk factors identified from time to time in the Company's SEC reports, including the Company's Annual Report on Form 10-K filed with the SEC. Except as expressly required by the federal securities laws, we undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, changes in circumstances or any other reason.
Contacts
Microvision
Media:
Matt Nichols, 206-940-4318
or
Maria Vetrano, 617-876-2770
or
Investors:
Tiffany Bradford, 425-936-6847
or
these low priced shells usually pull a reverse split as part of the process, imo
ROHI company info...
Rotech Healthcare Inc., together with its subsidiaries, provides home medical equipment and related products and services in the United States. It rents and sells oxygen and other respiratory therapy equipment and services, including oxygen concentrators, liquid oxygen systems, high pressure oxygen cylinders, homefill systems, portable oxygen concentrators, continuous positive airway pressure devices and supplies, bi-level positive airway pressure devices and supplies, non-invasive positive pressure ventilator devices and supplies, and nebulizer devices and medications. The company also sells and rents a line of durable medical equipment, such as hospital beds, wheelchairs, walkers, patient aids, and other ancillary supplies. Its patient service technicians or clinicians provide instruction and training to the patient and the patient?s family regarding equipment use and maintenance for the prescribed therapy. In addition, the company?s activities include reimbursement by third-party payors comprising Medicare, Medicaid, the Veterans Administration, and private insurers. Rotech Healthcare Inc. serves older patients with breathing disorders, such as chronic obstructive pulmonary diseases, which include chronic bronchitis, emphysema, obstructive sleep apnea, and other cardiopulmonary disorders. As of December 31, 2009, it had approximately 450 operating locations located primarily in non-urban markets in 48 states. The company was founded in 1981 and is headquartered in Orlando, Florida.
ROHI company info
Rotech Healthcare Inc., together with its subsidiaries, provides home medical equipment and related products and services in the United States. It rents and sells oxygen and other respiratory therapy equipment and services, including oxygen concentrators, liquid oxygen systems, high pressure oxygen cylinders, homefill systems, portable oxygen concentrators, continuous positive airway pressure devices and supplies, bi-level positive airway pressure devices and supplies, non-invasive positive pressure ventilator devices and supplies, and nebulizer devices and medications. The company also sells and rents a line of durable medical equipment, such as hospital beds, wheelchairs, walkers, patient aids, and other ancillary supplies. Its patient service technicians or clinicians provide instruction and training to the patient and the patient?s family regarding equipment use and maintenance for the prescribed therapy. In addition, the company?s activities include reimbursement by third-party payors comprising Medicare, Medicaid, the Veterans Administration, and private insurers. Rotech Healthcare Inc. serves older patients with breathing disorders, such as chronic obstructive pulmonary diseases, which include chronic bronchitis, emphysema, obstructive sleep apnea, and other cardiopulmonary disorders. As of December 31, 2009, it had approximately 450 operating locations located primarily in non-urban markets in 48 states. The company was founded in 1981 and is headquartered in Orlando, Florida.
Just watched it on Fox news, fair and balanced, said it was a deep quake, not much damage initially
Must be Bush's fault, all of the natural disasters get blamed on him by the Libs
ROHI going to be the play of the week, looking for $1 ++
stockcharts.com/h-sc/ui?s=rohi
ROHI chart a beauty, thanks much, certainly looks like it's just starting up, a run into the $1 ++ range is looking better every day.
ROHI monster
Been some solid buying of late, and with the low float and rising price, we could be witnessing a perfect storm with this gem
check the post it above, the link is there for the contract they signed....I'm looking for $1 + next week
ROHI $1 + next week
well, ROHI has just 25 million shares OS and has a HUGE contract, $88 million according to the Yahoo boards....tightly held and looking for $1 + next week
ROHI been unreal
have traded it maany times
ROHI been on fire of late.....low floater up
ROHI goung here
looking for .10+ today
MORE NEWS !!!
Cord Blood America's CEO Matthew Schissler, In Analyst Interview, Discusses China Expansion
Last update: 4/1/2010 5:00:00 AM
LAS VEGAS, April 1, 2010 /PRNewswire via COMTEX/ -- Cord Blood America, Inc. (CBAI), the umbilical cord blood stem cell preservation company ( ), is focused on bringing the life saving potential of stem cells, a biological insurance policy, to families nationwide and internationally. Its CEO and co-founder, Matthew Schissler, in an interview with analyst Francis Gaskins, said its recent announcement to build the world's largest stem cell storage facility in China, in conjunction with AXM Pharma, Inc. (Pink Sheets: AXMP), makes great sense for three reasons:
A higher percentage of Chinese are interested in storing stem cells than in populations in the U.S. and Europe.
The barriers to entry into China are high and expensive. By partnering with a Company which is already successful, and which holds key government licenses, Cord Blood America sees a pathway to success.
China is the world's most populous country and Cord Blood America needs representation there to move forward with its worldwide growth strategy.
The entire interview is available at
The interview also features a discussion by Mr. Schissler of the Company's annual financial report, which was filed with the U.S. Securities & Exchange Commission this week. "We now have a healthy balance sheet compared to where we were 12 months ago," CBAI's CEO said. "The year 2010 will be dedicated to growing revenues."
About Cord Blood America
Cord Blood America (CBAI) is the parent company of CorCell, which facilitates umbilical cord blood stem cell preservation for expectant parents and their children. Its mission is to be the most respected stem cell preservation company in the industry. Collected through a safe and non-invasive process, cord blood stem cells offer a powerful and potentially life-saving resource for treating a growing number of ailments, including cancer, leukemia, blood, and immune disorders. To find out more about Cord Blood America, Inc. (CBAI), visit our website at . For investor information, visit .
CONTACT: Paul Knopick E & E Communications 949/707-5365 pknopick@eandecommunications.com
SOURCE Cord Blood America, Inc.
Copyright (C) 2010 PR Newswire. All rights reserved
AXMP news this morning..runner to .10+
Cord Blood America's CEO Matthew Schissler, In Analyst Interview, Discusses China Expansion
Last update: 4/1/2010 5:00:00 AM
LAS VEGAS, April 1, 2010 /PRNewswire via COMTEX/ -- Cord Blood America, Inc. (CBAI), the umbilical cord blood stem cell preservation company ( ), is focused on bringing the life saving potential of stem cells, a biological insurance policy, to families nationwide and internationally. Its CEO and co-founder, Matthew Schissler, in an interview with analyst Francis Gaskins, said its recent announcement to build the world's largest stem cell storage facility in China, in conjunction with AXM Pharma, Inc. (Pink Sheets: AXMP), makes great sense for three reasons:
A higher percentage of Chinese are interested in storing stem cells than in populations in the U.S. and Europe.
The barriers to entry into China are high and expensive. By partnering with a Company which is already successful, and which holds key government licenses, Cord Blood America sees a pathway to success.
China is the world's most populous country and Cord Blood America needs representation there to move forward with its worldwide growth strategy.
The entire interview is available at
The interview also features a discussion by Mr. Schissler of the Company's annual financial report, which was filed with the U.S. Securities & Exchange Commission this week. "We now have a healthy balance sheet compared to where we were 12 months ago," CBAI's CEO said. "The year 2010 will be dedicated to growing revenues."
About Cord Blood America
Cord Blood America (CBAI) is the parent company of CorCell, which facilitates umbilical cord blood stem cell preservation for expectant parents and their children. Its mission is to be the most respected stem cell preservation company in the industry. Collected through a safe and non-invasive process, cord blood stem cells offer a powerful and potentially life-saving resource for treating a growing number of ailments, including cancer, leukemia, blood, and immune disorders. To find out more about Cord Blood America, Inc. (CBAI), visit our website at . For investor information, visit .
CONTACT: Paul Knopick E & E Communications 949/707-5365 pknopick@eandecommunications.com
SOURCE Cord Blood America, Inc.
Copyright (C) 2010 PR Newswire. All rights reserved
not here, but if it has a zero or two in front of it, i'm sure it'll do well here
COIN .92 x .92 here up 10%, can actually trade this AFTER HOURS
COIN up 10% on earnings AH...i know it doesn't have any zeroes in front of it and IS a real company
COIN bid UT .87 x .92
COIN going here on AH earnings news
COIN news out 10-k
Converted Organics Inc. Announces over $2.6 Million in Revenue
Shareholder Conference Call Scheduled to Review Business Developments
BOSTON--(BUSINESS WIRE)--Converted Organics Inc. (NASDAQ:COIN) announced today that the Company has filed its Form 10-K annual report with the Securities and Exchange Commission (SEC), announcing revenue of $2,634,000 for the year ended December 31, 2009.
“Converted Organics continues to be pleased with the progress of the Company”
"Converted Organics continues to be pleased with the progress of the Company," said Edward J. Gildea, President of Converted Organics. "We look forward to updating shareholders about the status of the business, including our recent acquisition activities."
Converted Organics' management will update shareholders on recent business developments in a conference call scheduled for 10:00 a.m. ET on Tuesday, April 6, 2010. Shareholders who wish to participate in the conference call may telephone (888) 567-1602 from the U.S. or (201) 604-5049 from international locations, approximately 15 minutes prior to the call. A digital replay will be available by telephone for two weeks and may be accessed by dialing (888) 632-8973 using digital replay code 47169167. The call will also be broadcasted simultaneously via a live webcast on the Converted Organics website at www.convertedorganics.com under the tab Investors and submenu Events & Presentations.
About Converted Organics Inc.
Converted Organics (NASDAQ: COIN, www.convertedorganics.com), based in Boston, MA, is dedicated to producing high-quality, all-natural, organic fertilizer products through food waste recycling.
This press release contains forward-looking statements that are subject to risks and uncertainties. These forward-looking statements include information about possible or assumed future results of our business, financial condition, liquidity, results of operations, plans and objectives. In some cases, you may identify forward-looking statements by words such as "may," "should," "plan," "intend," "potential," "continue," "believe," "expect," "predict," "anticipate" and "estimate," the negative of these words or other comparable words. These statements are only predictions. One should not place undue reliance on these forward-looking statements. The forward-looking statements are qualified by their terms and/or important factors, many of which are outside the company's control, involve a number of risks, uncertainties and other factors that could cause actual results and events to differ materially from the statements made. The forward-looking statements are based on the company's beliefs, assumptions and expectations of our future performance, taking into account information currently available to the company. These beliefs, assumptions and expectations can change as a result of many possible events or factors, including those events and factors, not all of which are known to the company, described in the "Risk Factors" section in the company's most recently filed annual report on Form 10-K, as updated in the company's quarterly reports on Form 10-Q filed since the annual report and most recently in the registration statement filed in relation to this offering. Neither the company nor any other person assumes responsibility for the accuracy or completeness of these statements. The company will update the information in this press release only to the extent required under applicable securities laws. If a change occurs, the company's business, financial condition, liquidity and results of operations may vary materially from those expressed in the aforementioned forward-looking statements.
COIN-G
Contacts
PR Financial Marketing
Investor Contact:
Jim Blackman, 713-256-0369
jim@prfmonline.com
or
Sterling Communications
Public Relations Contact:
Pat Fiaschetti, 908-996-7945
sterling.pf@att.net
COIN earnings news
Converted Organics Inc. Announces over $2.6 Million in Revenue
Shareholder Conference Call Scheduled to Review Business Developments
BOSTON--(BUSINESS WIRE)--Converted Organics Inc. (NASDAQ:COIN) announced today that the Company has filed its Form 10-K annual report with the Securities and Exchange Commission (SEC), announcing revenue of $2,634,000 for the year ended December 31, 2009.
“Converted Organics continues to be pleased with the progress of the Company”
"Converted Organics continues to be pleased with the progress of the Company," said Edward J. Gildea, President of Converted Organics. "We look forward to updating shareholders about the status of the business, including our recent acquisition activities."
Converted Organics' management will update shareholders on recent business developments in a conference call scheduled for 10:00 a.m. ET on Tuesday, April 6, 2010. Shareholders who wish to participate in the conference call may telephone (888) 567-1602 from the U.S. or (201) 604-5049 from international locations, approximately 15 minutes prior to the call. A digital replay will be available by telephone for two weeks and may be accessed by dialing (888) 632-8973 using digital replay code 47169167. The call will also be broadcasted simultaneously via a live webcast on the Converted Organics website at www.convertedorganics.com under the tab Investors and submenu Events & Presentations.
About Converted Organics Inc.
Converted Organics (NASDAQ: COIN, www.convertedorganics.com), based in Boston, MA, is dedicated to producing high-quality, all-natural, organic fertilizer products through food waste recycling.
This press release contains forward-looking statements that are subject to risks and uncertainties. These forward-looking statements include information about possible or assumed future results of our business, financial condition, liquidity, results of operations, plans and objectives. In some cases, you may identify forward-looking statements by words such as "may," "should," "plan," "intend," "potential," "continue," "believe," "expect," "predict," "anticipate" and "estimate," the negative of these words or other comparable words. These statements are only predictions. One should not place undue reliance on these forward-looking statements. The forward-looking statements are qualified by their terms and/or important factors, many of which are outside the company's control, involve a number of risks, uncertainties and other factors that could cause actual results and events to differ materially from the statements made. The forward-looking statements are based on the company's beliefs, assumptions and expectations of our future performance, taking into account information currently available to the company. These beliefs, assumptions and expectations can change as a result of many possible events or factors, including those events and factors, not all of which are known to the company, described in the "Risk Factors" section in the company's most recently filed annual report on Form 10-K, as updated in the company's quarterly reports on Form 10-Q filed since the annual report and most recently in the registration statement filed in relation to this offering. Neither the company nor any other person assumes responsibility for the accuracy or completeness of these statements. The company will update the information in this press release only to the extent required under applicable securities laws. If a change occurs, the company's business, financial condition, liquidity and results of operations may vary materially from those expressed in the aforementioned forward-looking statements.
COIN-G
Contacts
PR Financial Marketing
Investor Contact:
Jim Blackman, 713-256-0369
jim@prfmonline.com
or
Sterling Communications
Public Relations Contact:
Pat Fiaschetti, 908-996-7945
sterling.pf@att.net
RGDX news AH
Response Genetics, Inc. Reports Full Year 2009 and Fourth Quarter Financial Results
Fourth Quarter ResponseDX™ Revenue Increases 81 Percent from Third Quarter 2009
LOS ANGELES--(BUSINESS WIRE)--Response Genetics, Inc. (Nasdaq: RGDX), a company focused on the development and sale of molecular diagnostic tests for cancer, today announced consolidated financial results for the fourth quarter and year ended December 31, 2009, as well as an update on the Company’s ResponseDX™ sales activities.
“2009 was a very exciting year for Response Genetics as we saw significant growth and acceptance of our ResponseDX™ diagnostic tests. This trend has continued into 2010, with approximately 800 tests sold in March alone”
“2009 was a very exciting year for Response Genetics as we saw significant growth and acceptance of our ResponseDX™ diagnostic tests. This trend has continued into 2010, with approximately 800 tests sold in March alone,” said Kathleen Danenberg, Response Genetics president and CEO. “We continue to execute on our successful growth strategy; expanding our sales force, strengthening our balance sheet and establishing an international distribution network. For the coming year, we look forward to building on the momentum we have gained to further increase sales of our diagnostic tests and to advance our pipeline of products.”
Corporate Development Highlights
* ResponseDX™ Test Sales Continue to Ramp – Approximately 1,700 ResponseDX™ genetic tests were ordered in the fourth quarter of 2009. Revenue recorded from ResponseDX™ products increased 81 percent to $1.7 million in the fourth quarter of 2009, compared to $0.9 million in the third quarter of 2009. The Company continues to record revenues primarily on a cash basis from certain insurance providers until collection patterns are better determined. Cash collections continue to increase and we expect the cash associated with the majority of the tests processed during the fourth quarter of 2009 will be collected during the first quarter of 2010.
* Expanded Sales and Distribution – Response Genetics continued to expand its national sales force to meet demand for its Response DX™ tests, from three sales people in January 2009 to 15 currently. Company operations have seamlessly kept pace with the increased volume of ResponseDX™ tests to maintain the Company’s five-to-seven-day turnaround time. Response Genetics also established an international presence through a distribution partnership with Genetic Technologies, the largest private laboratory in Australia. ResponseDX™ tests are now available in Australia and certain Asian countries.
* Increased Reimbursement Due to Expanded ResponseDX™ Panels – With the addition of epidermal growth factor receptor (EGFR) mutational analysis, reimbursement of the Company’s ResponseDX: Lung™ panel increased from approximately $1,000 to $1,950, and ResponseDX: Colon™ test from approximately $950 to $1,100 with the addition of EGFR mutational analysis and BRAF mutational analysis. Approximately 50 percent of our ResponseDX™ revenue in 2009 was derived from our expanded ResponseDX: Lung™ panel. Response Genetics’ flexible technology allows the addition of new analytic capabilities as genes associated with therapeutic benefit to chemotherapy agents are identified.
* New ResponseDX™ Panel Launched Nationally – In September 2009, Response Genetics announced the nation-wide availability of its newest test panel, ResponseDX: Gastric™, a proprietary PCR-based diagnostic test that quantitatively analyzes three key genes – ERCC1, TS and HER2 – in tumors to help physicians make treatment decisions for patients with gastric cancer and gastroesophageal (GE) junction cancer. This new ResponseDX™ test is a product of the Company’s R&D pipeline and underscores its product development capabilities.
* $4 Million Private Placement – On March 5, 2010, Response Genetics entered into an agreement with funds managed by Lansdowne Partners Limited Partnership, Greenway Capital Partners and Paragon Associates whereby approximately $4 million was raised from a private placement of approximately 3 million newly issued shares of its common stock. Additionally, the Company announced two separate purchase agreements in 2009 with certain new and existing investors and raised a total of approximately $6 million. These funds are to be used by the Company to facilitate its sales goals and to expand its ResponseDX™ product offerings.
* Data Presented at ASCO and WCLC – At the annual meeting of the American Society of Clinical Oncology in Orlando, Response Genetics announced the results of studies identifying genes associated with positive chemotherapy outcome and tumor recurrence. And at the 13th World Conference on Lung Cancer in San Francisco, Response Genetics announced the results of separate analyses of KRAS gene mutations and TS and RRM1 gene expression in non-small cell lung cancer (NSCLC). These results, which were presented by Dr. David R. Gandara, University of California, Davis Cancer Center, and Dr. Philip Mack, University of California, Davis, provided insights into which patients are most likely to benefit from the commonly prescribed chemotherapies.
Financial Results for the Fourth Quarter Ended December 31, 2009
Total revenue increased by 134 percent to $3.4 million for the fourth quarter ended December 31, 2009, compared to $1.4 million for the same period last year. Revenue from our ResponseDX™ genetic tests, which we started to sell in the third quarter of 2008, increased to $1.7 million for the fourth quarter ended December 31, 2009, compared to $0.2 million for the same period in 2008. Our pharmaceutical client revenue increased 38 percent to $1.7 million, compared to $1.3 million in the fourth quarter of 2008.
Cost of revenue for the fourth quarter ended December 31, 2009 was $1.8 million, compared with $0.9 million for the same period ended 2008. Research and development expenses were $0.6 million for the fourth quarter of 2009, compared with $0.4 million for the same period in the prior year. General and administrative expenses were $1.6 million for the fourth quarter ended December 31, 2009, compared with $1.8 million for the same period in 2008. Selling and marketing costs primarily related to the expansion of our ResponseDX™ tests totaled $1.1 million compared with $0.4 million for the same period in the prior year. Total operating expenses for the fourth quarter of 2009 were $5.1 million, compared with $4.9 million for the same period last year. Included in total operating expenses were costs related to the continued expansion of the Company’s ResponseDX™ tests, and its costs related to marketing and its sales force additions, which totaled $1.1 million for the fourth quarter. The increase in total operating expenses in the fourth quarter of 2009 were offset by lower costs of $1.4 million for the operations of our United Kingdom laboratory due to the closure of that facility in March 2009.
Response Genetics’ net loss for the fourth quarter ended December 31, 2009 was $1.7 million, or $0.11 per share, compared with a net loss of $3.4 million, or $0.33 per share, for the same period last year.
Financial Results for the Year Ended December 31, 2009
Total revenue was $9.1 million for the year ended December 31, 2009, compared to $7.1 million for the year ended December 31, 2008, an increase of 28 percent. Revenue from our ResponseDX™ genetic tests totaled approximately $3.3 million. Our pharmaceutical client revenue decreased 16 percent to $5.8 million. As previously announced, this decrease was primarily due to a delay in the receipt of clinical samples from one of our major pharmaceutical clients, which the Company anticipates receiving in subsequent quarters through 2010.
Cost of revenue for the year ended December 31, 2009 was $5.7 million, compared with $4.0 million for the year ended December 31, 2008. Research and development expenses were $2.3 million for the year ended December 31, 2009, compared with $2.1 million for the year ended December 31, 2008. General and administrative expenses were $6.1 million for the year ended December 31, 2009, compared with $6.7 million for the year ended December 31, 2008. Selling and marketing costs primarily related to the expansion of our ResponseDX™ tests totaled $3.6 million for the year ended December 31, 2009 compared with $0.9 million for the same period in the prior year. Total costs for our now closed United Kingdom laboratory decreased to $0.7 million for the year ended December 31, 2009 compared to $3.4 million for the same period in 2008. Total operating expenses for the year ended December 31, 2009 were $18.5 million, compared with $17.0 million for the year ended December 31, 2008. The primary reasons for the increase in total operating expenses were costs related to the continued expansion of the Company’s ResponseDX™ tests and its sales force additions, which totaled $3.6 million for the year ended December 31, 2009. These expenses were offset by lower costs of 2.6 million for the operations of our United Kingdom lab due to the closure of that facility.
Response Genetics’ net loss for the twelve months ended December 31, 2009 was $9.3 million or $0.70 per share, compared with a net loss of $9.5 million, or $0.93 per share, for the same period last year.
Cash and Cash Equivalents
Cash and cash equivalents at December 31, 2009, were $7.1 million, compared to $9.5 million at December 31, 2008. As previously announced, Response Genetics completed a private placement of approximately 3.0 million newly issued common shares at a per-share price of $1.31. The Company received net proceeds of approximately $4.0 million from this private placement on March 5, 2010.
Reclassifications
Prior year amounts in the consolidated financial statements have been reclassified to conform to the current year presentation. Reclassified amounts had no impact on the Company’s net operating results.
About Response Genetics, Inc.
Response Genetics, Inc. (“RGI”) (the “Company”) (Nasdaq: RGDX) is engaged in the research and development of pharmacogenomic cancer diagnostic tests based on its proprietary and patented technologies. RGI’s technologies enable extraction and analysis of genetic information from genes derived from tumor samples stored as formalin-fixed and paraffin-embedded specimens. In addition to diagnostic testing services, RGI generates revenue from the sales of its proprietary analytical pharmacogenomic testing services of clinical trial specimens to the pharmaceutical industry. The Company was founded in 1999 and its principal headquarters are located in Los Angeles, California. For more information, please visit www.responsegenetics.com.
Forward-Looking Statement Notice
Except for the historical information contained herein, this press release and the statements of representatives of RGI related thereto contain or may contain, among other things, certain forward-looking statements, within the meaning of the Private Securities Litigation Reform Act of 1995.
Such forward-looking statements involve significant risks and uncertainties. Such statements may include, without limitation, statements with respect to the Company’s plans, objectives, projections, expectations and intentions, such as the ability of the Company to analyze cancer samples, the potential for using the results of this research to develop diagnostic tests for cancer, the usefulness of genetic information to tailor treatment to patients, the ability of the Company to expand its ResponseDX: Lung™ and ResponseDX: Colon™ test availability, the ability of the Company to continue to offer its ResponseDX Gastric™ tests, the ability of the Company to maintain or receive increased reimbursement of its tests, the ability of the Company to expand its sales force, the ability to continue to ramp the sales of ResponseDX and other statements identified by words such as “projects,” “may,” “could,” “would,” “should,” “believes,” “expects,” “anticipates,” “estimates,” “intends,” “plans” or similar expressions.
These statements are based upon the current beliefs and expectations of the Company’s management and are subject to significant risks and uncertainties, including those detailed in the Company’s filings with the Securities and Exchange Commission. Actual results, including, without limitation, actual sales results, if any, or the application of funds, may differ from those set forth in the forward-looking statements. These forward-looking statements involve certain risks and uncertainties that are subject to change based on various factors (many of which are beyond the Company’s control). The Company undertakes no obligation to publicly update forward-looking statements, whether because of new information, future events or otherwise, except as required by law.
RESPONSE GENETICS, INC.
CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS
Three Months Ended
December 31,
Year Ended
December 31,
2008
2009
2008 2009
(Unaudited)
(Unaudited)
Net revenue $ 1,441,362 $ 3,371,695 $ 7,124,771 $ 9,066,683
Operating expenses:
Cost of revenue 867,518 1,822,696 3,965,888 5,720,825
Selling and marketing 352,623 1,113,693 878,706 3,621,030
General and administrative 1,811,552 1,632,424 6,679,992 6,085,628
UK operating expenses 1,431,685 18,617 3,371,513 752,901
Research and development 433,044 559,080 2,088,832 2,293,303
Total operating expenses 4,896,422 5,146,510 16,984,931 18,473,687
Operating loss (3,455,060 ) (1,774,815 ) (9,860,160 ) (9,407,004 )
Other income (expense):
Interest expense (848 ) (2,623 ) (3,875 ) (10,822 )
Interest income 55,276 108 374,659 22,265
Other (5,219 ) 49,718 (8,911 ) 49,718
Loss before income taxes (3,405,851 ) (1,727,612 ) (9,498,287 ) (9,345,843 )
Provision for income taxes (12,749 ) (4,788) (12,749 ) (4,788)
Net loss $ (3,393,102 ) $ (1,722,824 ) $ (9,485,538 ) $ (9,341,055 )
Unrealized loss on foreign currency translation - 10,642 - 46,350
Total comprehensive loss $ (3,393,102 ) $ (1,712,182 ) $ (9,485,538 ) $ (9,294,705 )
Net loss per share — basic and diluted $ (0.33 ) $ (0.11 ) $ (0.93 ) $
(0.70
)
Weighted-average common shares — basic and diluted
10,239,276
15,297,183 10,239,276 13,276,095
Contacts
Trout Group
Investor Relations:
Peter Rahmer, 646-272-8526
or
Fleishman-Hillard
Media Relations:
Barry Sudbeck, 415-318-4261